Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(3E)-4-(1-methyl–1H-indol–3–yl)but–3–en–2–one is a synthetic small molecule belonging to the n‑alkylindoles class, characterized by an indole moiety with a methyl group at the nitrogen and a butenone side chain. It has been identified as an experimental compound with potential biological activities, including anticancer and anti-inflammatory effects. Its primary known molecular target is histone acetyltransferase KAT2B, suggesting it may act as an epigenetic modulator by influencing histone acetylation and gene expression[1][4]. There are no approved therapeutic indications or marketed products containing this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (3E)-4-(1-methyl-1H-indol-3-yl)but-3-en-2-one.